Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

January 30, 2014

CT Innovations adds to Branford pharma investment

Branford’s New Haven Pharmaceuticals has raised $1.6 million from several investors, including Connecticut Innovations, which announced the deal.

The company will use the funds to help it advance its first drug product, Durlaza, which is meant to be a secondary prevention for strokes and acute cardiovascular events.

NHP is also developing stomach acid treatments, using technology licensed from Yale.

CI’s follow-on investment of $361,695 brings its total investment in the company to nearly $1.9 million.

Other investors included EJ Funds, Advantage Capital Partners, Kuzari Group and NHP CEO Patrick Fourteau.

Sign up for Enews

Most Popular

Most Popular

Related Content

CT Innovations makes $1.25M investment in Colorado cannabis business relocating to state
Five years in, Hartford’s startup scene grows but is still in early stages
CI’s VentureClash pitch competition fades as startup incubators take on larger role
Thumbnail CT Innovations leads $10M investment in Israeli medical device maker

0 Comments

Order a PDF